Yang, J <br/><br/>
Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.  [electronic resource] 

 -  Journal of clinical pharmacy and therapeutics  Dec 2014 
 - 680-4 p.  digital 
<br/><br/> Publication Type: Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1365-2710 
<br/><br/><label>Standard No.: </label>10.1111/jcpt.12193  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Aniline Compounds--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Area Under Curve<br/>Cytochrome P-450 CYP3A--biosynthesis<br/>Cytochrome P-450 CYP3A Inducers--pharmacology<br/>Drug Interactions<br/>Female<br/>Half-Life<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors<br/>Rifampin--pharmacology<br/>Sulfonamides--adverse effects<br/>bcl-X Protein--antagonists & inhibitors